Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose safety, tolerability, and pharmacokinetics of MK-2214 in healthy Japanese adults
jRCT2031220627Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mk-2214 in Alzheimer's disease (AD) (8 arms), sponsored by Merck & Co. Primary endpoint: Adverse events. Started Mar 2023; status: completed.
02
Drugs
mk-2214
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031220627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220627.